| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802898901036 | 289890103 | RENVELA F.C.TAB 800MG/TAB Φιάλη (HDPE)x 180 | 73.94 | 77.57 | 98.66 |
| 05/2018 | 2802898903016 | 289890301 | RENVELA PD.ORA.SUS 2,4G/SACHET BTx60 SACHETS (LDPE) | 125.67 | 131.83 | 162.10 |
For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.
Sevelamer prevents hyperphosphatemia by binding to dietary phosphate in the gut, preventing its absorption and thus decreasing serum parathyroid hormone levels.
Sevelamer has been given to normal healthy volunteers in doses of up to 14 grams per day for eight days with no adverse effects. Sevelamer has been given in average doses up to 13 grams per day to hemodialysis patients. There are no reported overdosages of sevelamer in patients. Since sevelamer is not absorbed, the risk of systemic toxicity is low.
Not absorbed following oral administration, however no absorption studies have been performed in patients with renal disease.